

Phase 1 BOIN Dose Escalation (N = 54)		Phase 2 (N = 160)				
ALK+ Solid Tumors ¹		COHORT	N	TUMOR TYPE	PRIOR ALK TKI ²	Prior Chemo and/or IO
ALK+ Solid Tumors ¹	200 mg QD	2a	40	ALK fusion+ NSCLC	1 prior 2 nd generation (ceritinib, alectinib, or brigatinib)	0-2 lines
	150 mg QD	2b	40	ALK fusion+ NSCLC	2-3 prior 1 st or 2 nd generation (ceritinib, ceritinib, alectinib, or brigatinib)	0-2 lines
	100 mg QD	2c	40	ALK fusion+ NSCLC	2-3 prior with brigatinib in 1 st or 2 nd line of therapy	0-2 lines
	50 mg QD	2d ³	40	Other ALK+ solid tumors & other ALK+ NSCLC not eligible for 2a-c	2-3 prior systemic therapy (or for whom no satisfactory standard therapy exists)	Any
	25 mg QD					
	15 mg QD					
Safety, Tolerability, MTD & RP2D		Efficacy endpoints include ORR (primary), DOR, measures of intracranial activity Pre-specified analyses include patients with NSCLC and ALK resistance mutations of interest				

¹Patients with ALK fusion-positive NSCLC must have previously received ≥1 ALK TKI, one of which must be a 2nd or 3rd generation TKI (ceritinib, alectinib, or brigatinib), while those with other solid tumors must have previously received ≥1 prior systemic anticancer therapy or be those for whom no satisfactory standard therapy exists.

²Excluding investigational agents targeting ALK (except for cohort 2d).

³Exploratory cohort, includes patients age ≥12 years with weight >40 kg.

ALK+, Positive for Anaplastic Lymphoma Kinase fusion or mutation; MTD, Maximum Tolerated Dose; NSCLC, Non-small cell lung cancer; RP2D, Recommended Phase 2 Dose; TKI, Tyrosine Kinase Inhibitor

FIG. 1

2/18




FIG. 2




FIG. 3




FIG. 4





FIG. 5

6/18



	Crizotinib	Ceritinib	Alectinib	Brigatinib	Lorlatinib	Compound 1
IC50	506.8	456.8	469.6	161.5	179.1	0.02920

FIG. 6

7/18




FIG. 7




FIG. 8B

FIG. 8A











FIG. 8D

FIG. 8C



10/18




FIG. 10




FIG. 11

11/18




FIG. 12




FIG. 13

12/18




FIG. 14




FIG. 15

13/18




FIG. 16

14/18




FIG. 17

15/18




FIG. 18

Osimertinib (nM)	0	3	100	0	3	100	0	3	100
Compound 1 (nM)	0			3			100		
pEGFR									
pALK									
pERK/AKT/S6									
Actin									

FIG. 19




FIG. 20A




FIG. 20B




FIG. 21




FIG. 22




FIG. 23A

FIG. 23B

18/18




FIG. 24A




FIG. 24B